Needham ups Alcon target, adds to Conviction List
Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%)
Reasons to Retain Alcon Stock in Your Portfolio for Now
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alcon: Q3, Slight Guidance Cut Is Not Something Structural
I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expected to drive significant growth in the vision segment. Alcon's surgical business, with a strong position in cataract surgery, is projected to grow 7% annually, driven by advanced technology and international expansion.
Alcon (ALC) Q3 2024 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Dan Cravens - Vice President, Investor Relations Conference Call Participants Graham Doyle - UBS Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co. Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Ryan Zimmerman - BTIG Jeff Johnson - Baird Anthony Petrone - Mizuho Tom Stephan - Stifel Brett Fishbin - Keybanc Capital Markets David Adlington - JP Morgan Giang Nguyen - Citi Issie Kirby - Redburn Atlantic Sajid Aznar - HSBC Falco Freidrichs - Deutsche Bank Operator Greetings and welcome to the Alcon third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode.
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
Alcon cuts 2024 forecasts, as slow US hits surgical unit
Eye-care group Alcon cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business.
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Reasons to Retain Alcon Stock in Your Portfolio for Now
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
